Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Multiple myeloma, the second most common haematopoietic cancer, represents a collection of plasma-cell neoplasms that invariably become fatal when self-renewing myeloma cells begin unrestrained proliferation. The major clinical manifestation of multiple myeloma is related to loss of bone through ost...
Main Authors: | J V Lobato, J M Rodrigues, M V Cavaleiro, J M Lobato, L Xavier, J D Santos, Ana C Maurício |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2007-04-01
|
Series: | Acta Médica Portuguesa |
Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/838 |
Similar Items
-
Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000) -
Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001) -
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000) -
P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
by: Maria Nieves Lopez Muñoz, et al.
Published: (2023-08-01) -
Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)